StockTake: Lumos grows US Medicare coverage for FebriDx point-of-care respiratory test

Stockhead’s Tylah Tully looks at Lumos Diagnostics’ (ASX:LDX) latest milestone.

The company continues to grows US Medicare coverage for FebriDx, its rapid point-of-care diagnostic test to differentiate between bacterial and non-bacterial acute respiratory infections.

Lumos now has Medicare reimbursement from 6 of 7 Medicare Administrative contractors, representing more than 85 per cent of total US Medicare payment coverage.  

This video was developed in collaboration with Lumos Diagnostics, a Stockhead advertiser at the time of publishing.

This video does not constitute financial product advice. You should consider obtaining independent advice before making any financial.